Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exosomes of MSC for MODS after ATAAD Repair
NCT04356300Not yet recruiting
- Sponsor
- Fujian Medical University
- Start
- Sep 2020
- Primary completion
- Sep 2021
- Modality
- Lipid-based Nanoparticles, Cell Therapies
01
Overview
Randomised, open-label trial of umbilical cord derived mesenchymal stem cells exosomes in multiple organ dysfunction syndrome (MODS) (2 arms), sponsored by Fujian Medical University. Primary endpoints: survival after intervention at 6 months, sequential organ failure assessment score at 6 months and 3 more. Planned start Sep 2020; status: not yet recruiting.
02
Drugs
umbilical cord derived mesenchymal stem cells exosomes
03
Conditions
multiple organ dysfunction syndrome (MODS)
Beyond the preview
Go deeper on NCT04356300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04356300.